Roxana Naderi, MD
Internal Medicine · Roseville, CANPI 1871936070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 33.4% of the total. Reporting peaked in 2021 at $121 and has fallen 76.4% since, to $29 in 2024.
Across 15 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$93
- Abbott$68
- Amgen$34
- Dynavax Technologies Corporation$25
- Biohaven Pharmaceuticals, Inc.$19
- AstraZeneca$15
- plus $24 from 2 others
What the payments were for
- Food & beverage$278100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 5 | $93 |
| Abbott | 3 | $68 |
| Amgen | 2 | $34 |
| Dynavax Technologies Corporation | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| AstraZeneca | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Lupin Inc. | 1 | $11 |
How this compares
$278 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PaxlovidNirmatrelvir/Ritonavir | 32 | $2,708 |
| Estradiol | 17 | $1,331 |
| Atorvastatin Calcium | 84 | $758 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $508 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 41 | $371 |
| Losartan Potassium | 29 | $346 |
| Levothyroxine Sodium | 37 | $337 |
| Rosuvastatin Calcium | 17 | $331 |
| Omeprazole | 21 | $327 |
| Doxycycline Hyclate | 19 | $285 |
| Gabapentin | 20 | $244 |
| Montelukast Sodium | 20 | $224 |
| Duloxetine Hcl | 14 | $218 |
| Lisinopril | 26 | $199 |
| Paxlovid (Eua)Nirmatrelvir/Ritonavir | 18 | $196 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Roseville
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.